The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

 Market Overview

The peptide-based metabolic disorders therapeutics market has seen significant growth in recent years.

• 2023 Market Size: $26.03 billion.
• 2024 Forecast: Expected to reach $29.89 billion.
• CAGR: 14.8% from 2023 to 2024.

Factors Driving Growth

• Prevalence of Metabolic Disorders: Increase in disorders like diabetes and obesity.
• Advancements in Peptide Synthesis: Improved technologies boosting drug development.
• Healthcare Expenditure: Rising global healthcare spending.
• Aging Population: Growing number of elderly patients requiring treatment.
• Biopharmaceutical Expansion: Industry growth leading to more peptide-based therapies.
• Regulatory Approvals: More therapies receiving green light from authorities.
• Personalized Medicine: Increased awareness and adoption.

View More On The Peptide Based Metabolic Disorders Therapeutics Market Report 2024 –
https://www.thebusinessresearchcompany.com/report/peptide-based-metabolic-disorders-therapeutics-global-market-report

Future Market Projections

• 2028 Market Size: Expected to grow to $52.16 billion.
• CAGR: 14.9% from 2024 to 2028.

Key Drivers for Future Growth

• Development of Novel Peptide Analogs: Introduction of new and effective treatments.
• R&D Investments: Increasing investments in research for metabolic disorders.
• Precision Medicine: Growing adoption of targeted therapies.
• Emerging Markets: Expansion in regions like Asia-Pacific.
• Collaborations in Drug Development: Partnerships accelerating innovation.
• Advancements in Delivery Technologies: Enhanced drug delivery methods.
• Patient-Centric Therapies: Focus on improving patient experiences and outcomes.

Emerging Trends in the Market

• AI in Drug Discovery: Artificial intelligence accelerating research.
• Personalized Therapies: Tailored treatments becoming mainstream.
• CRISPR/Cas9 Utilization: Gene-editing technologies being integrated.
• Wearable Devices: Devices for continuous patient monitoring.
• Oral Peptide Formulations: Development of oral delivery options.
• Digital Therapeutics: Rise in digital tools for managing diseases.
• Biobanking: Expansion of biobanks for personalized treatment options.

Obesity’s Role in Market Expansion

• Obesity’s Impact: Rising obesity rates driving demand for peptide-based therapies.
• Contributing Factors:
  • Sedentary lifestyles.
  • Unhealthy diets.
  • Genetic predisposition.
• Therapeutic Focus:
  • Regulating metabolic functions.
  • Improving insulin sensitivity.
  • Controlling appetite.

Notable Companies in the Market

• Key Players:
  • Pfizer Inc., Johnson & Johnson, Roche Holding AG.
  • Merck & Co. Inc., AbbVie Inc., Sanofi SA.
  • Bristol-Myers Squibb, AstraZeneca, Novartis AG.
  • Takeda Pharmaceutical, GlaxoSmithKline, Boehringer Ingelheim.
  • Eli Lilly, Amgen, Gilead Sciences, Novo Nordisk.
  • Teva Pharmaceutical, Regeneron, Biogen, Vertex, Jazz Pharmaceuticals.

Innovation in Biosimilars

• Biosimilars in Focus:
  • Companies developing peptide-based anti-diabetic biosimilars.
  • Example: Glenmark Pharmaceuticals launched Lirafit, a biosimilar of Liraglutide, in January 2024.
  • Benefits:

• Lowering glycemic levels.
• Promoting weight reduction.
• Enhancing cardiovascular safety.

Strategic Acquisitions

• Roche’s Acquisition of Carmot Therapeutics:
  • Deal Value: $2.7 billion in December 2023.
  • Acquisition Focus: Clinical-stage incretins like CT-388 for obesity treatment.
  • Company Overview: Carmot Therapeutics specializes in peptide-based therapeutics for metabolic disorders.

Geographic Insights

• Largest Region: North America dominated the market in 2023.
• Fastest-Growing Region: Asia-Pacific expected to lead growth in the coming years.

The peptide-based metabolic disorders therapeutics market is poised for robust expansion, driven by innovation, strategic investments, and a growing need for effective treatments.

Request A Sample Of The Global Peptide Based Metabolic Disorders Therapeutics Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=16764&type=smp